Belimumab : a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis

Article English OPEN
Kandala, Ngianga-Bakwin ; Connock, M. ; Grove, Amy L. ; Sutcliffe, P. (Paul) ; Mohiuddin, Syed ; Hartley, Louise ; Court, Rachel A. ; Cummins, E. ; Gordon, Caroline ; Clarke, Aileen (2013)
  • Publisher: BMJ
  • Journal: BMJ Open (vol: 3)
  • Related identifiers: doi: 10.1136/bmjopen-2013-002852, pmc: PMC3717447
  • Subject: Preventive Medicine | RA0421 | 1692 | Research | 1723 | Epidemiology | 1694 | Clinical Pharmacology | RM | 1705 | 1506 | Public Health | 1724 | R1
    mesheuropmc: skin and connective tissue diseases

Objectives: To undertake a systematic review and meta-analysis to investigate clinical effectiveness of belimumab for patients with systemic lupus erythematosus (SLE) and antinuclear and/or anti-double-stranded DNA (dsDNA) autoantibodies.\ud Methods: We searched eight electronic databases and reference lists for randomised controlled trials (RCTs) of belimumab against placebo or best supportive care. Quality assessment and random effects meta-analysis were undertaken.\ud Design: A meta-analysis of RCTs.\ud Participants: 2133 SLE patients.\ud Primary and secondary outcome measures: SLE Responder Index (SRI) at week 52.\ud Results: Three double-blind placebo-controlled RCTs (L02, BLISS-52 BLISS-76) investigated 2133 SLE patients. BLISS-52 and BLISS-76 trials recruited patients with antinuclear and/or anti-dsDNA autoantibodies and demonstrated belimumab effectiveness for the SRI at week 52. Ethnicity and geographical location of participants varied considerably between BLISS trials. Although tests for statistical heterogeneity were negative, BLISS-52 results were systematically more favourable for all measured outcomes. Meta-analysis of pooled 52-week SRI BLISS results showed benefit for belimumab (OR 1.63, 95% CI 1.27 to 2.09). By week 76, the primary SRI outcome in BLISS-76 was not statistically significant (OR 1.31, 95% CI 0.919 to 1.855).
  • References (44)
    44 references, page 1 of 5

    1. Bernatsky S, Joseph L, Pineau CA, et al. A population-based assessment of systemic lupus erythematosus incidence and prevalence-results and implications of using administrative data for epidemiological studies. Rheumatology (Oxford) 2007;46:1814-18.

    2. Pons-Estel GJ, Alarcon GS, Scofield L, et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010;39:257-68.

    3. Gordon C, Li CK, Isenberg DA. Systemic lupus erythematosus. Medicine 2010;38:73-80.

    4. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.

    5. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.

    6. Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 2005;19:685-708.

    7. Somers EC, Thomas SL, Smeeth L, et al. Incidence of systemic lupus erythematosus in the United Kingdom, 1990-1999. Arthritis Rheum 2007;57:612-18.

    8. Pons-Estel GJ, Alarcon GS, McGwin G Jr, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 2009;61:830-9.

    9. Pons-Estel GJ, Gonzalez LA, Zhang J, et al. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology (Oxford) 2009;48:817-22.

    10. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54:2550-7.

  • Similar Research Results (1)
  • Metrics
    No metrics available
Share - Bookmark